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Advances in Stroke
Advances in Emerging Therapies 2009
Kate McArthur, MRCP; Kennedy R. Lees, MD, FRCP
Stroke has multiple etiologies and presents in many forms.Therefore, it will continue to pose challenges in preven-
tion, diagnosis, and treatment. 2009 has brought modest
advances in terms of new acute stroke therapies but has
provided encouraging preliminary reports of possible devel-
opments to come. The main progress of 2009 has been in the
area of primary and secondary prevention, providing exciting
new therapies that are likely to alter our practice significantly
in the future. Prevention is better than cure.
Primary Prevention
Statins have a role alongside antithrombotic and antihyper-
tensive agents for secondary prevention of stroke.1 The
JUPITER investigators recently demonstrated the efficacy of
a statin for primary prevention.2
JUPITER was a randomized, double-blind, placebo-
controlled trial of high-dose rosuvastatin (20 mg per day).
The study population consisted of 17 802 apparently
healthy men (50 years of age) and women (60 years of
age) who, at screening, had low levels of low-density
lipoprotein cholesterol (3.4 mmol/L) and increased lev-
els of high-sensitivity C-reactive protein (2.0 mg/L).
Nearly 90 000 patients had to be screened to attain this
enrollment. The trial was stopped early after median
follow-up of only 1.9 years of the planned 4 because of a
striking reduction in the primary end point of first major
cardiovascular event: 0.77 versus 1.36 events per 100
person years of follow-up, respectively (hazard ratio for
rosuvastatin, 0.56; 95% CI, 0.46 to 0.69; P0.00001). Of
these major cardiovascular events, there were 33 strokes in
the rosuvastatin group (n8901) and 64 strokes in the
placebo group (n8901). This 48% reduction in stroke risk
was found to be driven by a reduction in ischemic
cerebrovascular events. There were similar numbers of
hemorrhagic stroke in both groups. Subgroup analysis
suggested that the patients who gained most benefit from
rosuvastatin therapy were those with increased traditional
risk factors, such as male sex, increasing age, and smok-
ing. The treatment was well tolerated apart from a small
but significant excess of new diabetes in the rosuvastatin
group. This was not an adjudicated outcome measure and
requires further examination.
Interestingly, JUPITER also reported a statistically signif-
icant reduction in deep venous thrombosis rates among
patients treated with rosuvastatin (0.09 versus 0.20 events per
100 person years of follow-up, respectively (hazard ratio for
rosuvastatin, 0.45; 95% CI, 0.25 to 0.79).3 There was a
reduction in venous thromboembolism as a whole, driven by
statistically significant reduction in deep venous thrombosis
and all “provoked” thromboembolism (ie, events occurring in
the presence of malignancy, hospitalization, surgery, or
trauma). The lipid-lowering effect of statin therapy alone
does not readily explain this reduction in venous thrombo-
embolism, but pleiotropic effects of statin therapy have been
proposed previously. Anticoagulant or anti-inflammatory ef-
fects may be present.
With the results of JUPITER in mind, the question re-
mains: at what point does the economic and clinical burden of
primary prevention become worthwhile? The JUPITER re-
ports may make us reconsider the scope of primary preven-
tion, but relative costs and benefits must be carefully assessed
before routine practice is changed.
Secondary Prevention
Embolic stroke caused by atrial fibrillation is associated with
high rates of mortality and disability. Two large randomized
control trials in atrial fibrillation appear likely to alter future
practice.
Effective anticoagulation has achieved the most significant
reduction in rates of atrial fibrillation–related stroke disease
in recent decades, primarily using vitamin K antagonists.
Warfarin prevents 64% of strokes in patients with nonvalvu-
lar atrial fibrillation.4 However, it is an unsatisfactory drug in
many respects. Most seriously, it is associated with in-
creased hemorrhagic events that can be catastrophic. The
narrow therapeutic index and susceptibility to interactions
mandate regular laboratory monitoring with clear eco-
nomic and practical implications. Despite best efforts,
control of anticoagulation is suboptimal in a sizeable
minority of patients, leaving them at increased risk of
thromboembolism or major hemorrhage.
In the search for a novel approach to anticoagulation
without the limitations of vitamin K antagonists, several
drugs have been investigated. Some have similar efficacy to
warfarin, at the expense of increased adverse effects. Ximel-
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agatran, a direct thrombin inhibitor caused unacceptable rates
of liver toxicity comparable warfarin in the SPORTIF V
trial.5 The AMADEUS trial was stopped early because of
increased rates of major bleeding in the group treated with
subcutaneous idraparinux, a synthetic pentasaccharide that
specifically inhibits activated factor X, compared with
warfarin.6
The RE-LY study has revived hope that effective anti-
coagulation may be possible with a drug that is easy to
administer and is free from significant interactions or
adverse effects.7 A total of 18 113 patients with atrial
fibrillation and increased risk of stroke were randomized to
receive either open-label dose-adjusted warfarin or one of
2 doses of dabigatran (110 mg twice daily or 150 mg twice
daily, respectively) administered in a blinded fashion.
Dabigatran is an oral prodrug that, once converted to its
active form, inhibits thrombin. It has a favorable profile in
terms of dietary and drug interactions because it is metab-
olized independently of cytochrome p-450. The trial found
neither dose of dabigatran to be inferior to warfarin with
respect to the primary outcome of systemic embolism or
stroke. Instead, the rate of systemic embolism or stroke
was significantly lower with the higher dose of dabigatran
(1.11% per year) than with either warfarin (1.69% per
year) or dabigatran at the lower dose regime (1.53% per
year). In terms of safety, the performance of dabigatran
was encouraging, especially when weighed against the
inconvenience and risks of warfarin prescribed outwith
trials. On the positive side, there were lower rates of
hemorrhagic stroke at both doses (0.12% per year and
0.10% per year, respectively) compared with warfarin
(0.38% per year) and comparable rates of extracranial
hemorrhage in all 3 groups. The rate of hepatotoxicity, as
defined by a rise in transaminase levels to 3 times the
upper limit of the normal range, was similar in all 3 groups
and well below the level seen in the SPORTIF trials.
However, dyspepsia was noted with increased frequency in
each dabigatran group (11.8% per year and 11.3% per year,
respectively) when compared with warfarin (5.8% per
year). Of greater concern, the rate of myocardial infarction
was slightly higher with dabigatran (0.72% per year and
0.74% per year, respectively) than with warfarin (0.53%
per year). Similar results were seen in patients treated with
ximelagatran for acute deep venous thrombosis in the
THRIVE Study.8 A retrospective analysis in this study
found a higher rate of serious coronary events in the group
treated with ximelagatran (10 events in 1240 patients)
compared with those treated with enoxaparin or warfarin
(1 event in 1249 patients; P0.006). These small effects
may not outweigh the advantages of direct thrombin
inhibition but deserve closer examination.
An attractive prospect to reduce stroke incidence in pa-
tients with atrial fibrillation would be suppression of the
arrhythmia itself, a direct approach that has thus far proven
ineffective. Maintenance of sinus rhythm may reduce symp-
toms and improve quality of life, but no antiarrhythmic drug
has yet been shown to reduce the risk of stroke, arguably the
most significant potential consequence of atrial fibrillation.
The ATHENA investigators reported that dronedarone, a new
class-3 antiarrhythmic drug, reduces the incidence of hospi-
talization resulting from cardiovascular events or death in
patients with persistent or paroxysmal atrial fibrillation or
atrial flutter.9
Dronedarone is a complex, multichannel blocking agent
with a pharmacological profile similar to that of amiodarone
but with different relative effects on ion channels. Structur-
ally, there are important differences relative to amiodarone,
rendering it more lipophilic, with a resultant reduction in half
life to 24 hours, which successfully reduces tissue accumu-
lation. Dronedarone has no iodine component, eliminating
thyroid toxicity. Rates of thyroid- and pulmonary-related
adverse events were not significantly different between
groups in ATHENA; however, follow-up lasted one year
only, whereas many of the expected side effects of traditional
amiodarone therapy would be expected over a much longer
time scale.
A post hoc analysis of ATHENA10 suggested a reduction in
stroke in patients receiving usual care including antiplatelet/
anticoagulant therapy and rate control therapy. A total of
4628 patients were randomized to placebo or dronedarone
with follow-up for a minimum of one year. There was similar
use of antiplatelets and anticoagulants in each group. The
reduction in the risk of stroke was from 1.8% to 1.2% per year
(hazard ratio, 0.66; 95% CI, 0.46 to 0.96; P0.027), and this
effect was similar when adjusted for the use of oral antico-
agulant therapy. A higher baseline risk of stroke, expressed
by use of the CHADS2 score, was associated with a greater
effect of dronedarone. Patients with a CHADS2 score2 had
a significantly greater effect of dronedarone than those with a
CHADS2 score of 1 (P0.03).
There are obvious limitations to the post hoc stroke
analysis. As an outcome, strokes were not adjudicated,
possibly a reflection of the fact that an effect on stroke
incidence was unexpected. This affects the quality of data
collection regarding stroke incidence, but the trend is clear.
The lack of an established mechanism for stroke reduction
gives a focus for direction of further research. Improved
maintenance of sinus rhythm, with reduction of arrhythmic
burden, is an attractive explanation; however, dronedarone
was also proven to have a modest antihypertensive effect and
possible anti-ischemic effects. Could dronedarone have pleio-
tropic effects similar to those of statins?
The vision for management of patients with atrial
fibrillation and increased risk of stroke, as defined by a
CHADS2 score of 2, would be to use a reliable antiar-
rhythmic drug free of significant toxic effects in conjunc-
tion with a predictable and safe oral anticoagulant medi-
cation that requires minimal monitoring. Perhaps the
combination of dabigatran and dronedarone now offers a
realistic prospect of this.
Acute Therapies
After the publication of ECASS III in 2008, guideline groups
in several countries have recommended to increase the
thrombolysis window to 4.5 hours, using recombinant tissue
plasminogen activator (rt-PA). However, optimal recanaliza-
tion therapy remains a challenge to us all, and we strive to
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improve functional recovery in patients who present early
enough to be eligible for treatment.
There have been limited advances during 2009 in the use
of thrombolytic therapy, but this remains fertile ground.
The relative benefits of intra-arterial over intravenous
thrombolysis are intuitive but have yet to be proven given
the inevitable complexities and delays with this method of
delivery. Ongoing trials are investigating the relative
benefits of novel thrombolytic agents (such as tenecteplase
and desmotoplase) or the use of adjuvant therapy together
with alteplase. Possible adjuvants are varied, including the
addition of additional anticoagulant therapy (such as a
direct thrombin inhibitors or glycoprotein IIb/IIIa inhibi-
tors) or the delivery of transcranial sonolysis in conjunc-
tion with systemic microspheres, which have been shown
in animal models to improve delivery of rt-PA and increase
clot lysis.
Devices
Further information on endovascular mechanical clot re-
trieval comes from the final results of the Multi MERCI
study. Recanalization of cerebral vessels is associated with
good clinical outcomes.11 However, large vessel occlu-
sions are less responsive to conventional rt-PA therapy.
Multi MERCI,12 a single-arm prospective trial of 164
patients (131 of whom were treated with the newest
generation L5 retriever), investigated the use of mechani-
cal thrombectomy devices with and without adjuvant
intravenous or intra-arterial rt-PA. Results of the trial are
reassuring but difficult to translate to clinical outcomes in
the absence of control data. Multi MERCI demonstrated
that arterial canalization was achieved in 57% of patients
treated with the L5 retriever alone and 69.5% in patients
also receiving intra-arterial rt-PA. There was a 27%
absolute advantage in mortality between the group that
achieved recanalization and the group that did not. The
safety and complication rates with the new device ap-
peared favorable (5.5% procedural complication rate; 2.4%
device-related serious adverse event rate), even in the
context of previous IV rt-PA therapy. Marketing authori-
zation for devices is predicated on demonstration that they
function satisfactorily for their designed purpose (eg, to
remove thrombus), and this may be apparent from uncon-
trolled studies. Widespread clinical use requires a higher
level of evidence. Mechanical thrombectomy devices are
still being evaluated in randomized trials (MR RESCUE
and IMS III).
A novel device developed with the aim of reducing stroke
in patients with atrial fibrillation has been granted expedited
review status by the Food and Drug Administration for use in
a clinical trial.13 Evaluation of the Watchman Left Atrial
Appendage Closure Device in patients with atrial fibrillation
(Embolic Protection in Patients with Atrial Fibrillation–
PROTECT-AF) is under way in a prospective trial. The left
atrial appendage is thought to be a major source of emboli in
patients with nonrheumatic atrial fibrillation, and this device,
inserted percutaneously via femoral access and a transseptal
technique, is designed to occlude the left atrial appendage,
thereby removing this source of potential emboli. Options for
patients with atrial fibrillation appear to be improving.
Summary
2009 was a year with little firm evidence for immediate
change in practice but provided us with a large body of
stimulating research showing promise for the coming years.
Therapy for acute stroke is largely unchanged in the wake of
the advances made with ECASS-III; however, much work is
ongoing to optimize recanalization therapy.
The largest strides in 2009 were taken in the area of stroke
prevention. The most exciting area of development is in the
field of stroke prevention in atrial fibrillation, with what may
develop into a 3-pronged attack of reliable and safe antico-
agulation, improved rhythm control, and mechanical devices
to reduce embolic risk. The possibility of extending preven-
tative therapy with statins in appropriate healthy people
merits further investigation.
The development of effective preventative strategies will
always prove most efficient in terms of mortality, morbidity,
and health economics, and we should celebrate the advances
made by the stroke community. We can be confident that
age-adjusted stroke incidence will continue to fall, and the
outcome for patients who succumb will continue to improve
with the ongoing design and conduct of high-quality clinical
research.
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